Search results: (10000)
News Alarming Data on Prevalence and Insufficient Treatment of Hypertension in Working Age − Another Underestimated 'Civilization Epidemic'?
The National Cardiology Information System (NKIS), developed by the Czech Society of Cardiology in collaboration with the Institute of Health Information and Statistics (ÚZIS), has provided the first data on the prevalence of hypertension in the Czech population. It revealed that even the treatment of a significant risk factor for cardiovascular diseases – hypertension – is not well managed in the Czech Republic. About 40% of patients with hypertension do not have regular preventive check-ups with their general practitioner, while 40% of hypertensive patients are simultaneously of working age.
News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.
News INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines
What examinations should be conducted when suspecting hypertrophic cardiomyopathy, a hereditary disease caused by mutations in genes encoding cardiac muscle proteins? What is the subsequent procedure for monitoring patients and their at-risk relatives? The comprehensive infographic summarizes the current recommendations of American professional societies.
News How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
News Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
News Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
News Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of empagliflozin in patients with heart failure with a left ventricular ejection fraction (LV EF) > 40%. What insights does it provide regarding the impact on cardiovascular (CV) mortality or the need for hospitalization for heart failure (HHF) concerning left ventricular function?
News Benefit of Oral Semaglutide for Patients with Type 2 Diabetes in the General Practitioner's Office
Oral semaglutide is a modern antidiabetic suitable within primary care for people with type 2 diabetes, primarily due to its comprehensive action that includes not only reducing blood glucose and body weight but also a number of other favorable non-glycemic effects.
News Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists, angiologists, and internists will be able to prescribe it with reimbursement. This decision was made by the State Institute for Drug Control (SÚKL) in mid-April. Hundreds of thousands of Czechs suffering from this serious condition will now have access to another effective medication. The drug is manufactured by Boehringer Ingelheim.
News What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
A Spanish clinical study monitored the effect of administering probiotics as an adjunct therapy to non-surgical mechanical treatment of peri-implantitis. What did the study show regarding the effect on microbiome composition and overall clinical picture when a preparation containing Limosilactobacillus reuteri Prodentis was administered?
News Pain Management After Day Surgery
Effective pain control is a crucial part of recovery for patients after painful surgical procedures. In clinical practice, combined analgesia using paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) is commonly utilized, which, however, is not suitable for up to a quarter of patients. An alternative could be metamizole. A study published in the European Journal of Anaesthesiology evaluated the non-inferiority of the combination of paracetamol/metamizole versus paracetamol/ibuprofen in pain management for patients after day surgery.
News Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
Empagliflozin entered the market as an antidiabetic drug operating on the principle of reducing glucose reabsorption by the kidneys from the urine and increasing its excretion through urine. Thanks to its very favorable impact on cardiovascular (CV) risks, it has gradually become an important part of treatment in cardiology as well. On May 1st, the long-awaited expansion of its reimbursement from public health insurance (ZP) for symptomatic heart failure with mildly reduced and preserved left ventricular ejection fraction (EF LK) will take place. It will thus be possible to improve the prognosis and quality of life for patients with this diagnosis. However, upon the availability of clinically verified therapy, another challenge arises in the form of underdiagnosis of patients with heart failure with preserved EF LK.
News At the Crossroads: 5 Options for Alzheimer's Disease Pharmacotherapy
Currently, we have 5 basic options for the pharmacotherapy of Alzheimer's disease. Is memantine, one of the three cholinesterase inhibitors, or combination therapy the most effective? A review article by Japanese and American authors evaluates the literature on the safety and efficacy of cognitive treatments for Alzheimer's disease.
News How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells with varying degrees of risk of progression to acute myeloid leukemia (AML). The therapeutic options for this disease are continually evolving. But what is the impact of this diagnosis on patients' quality of life?